Skip to main content

Table 2 Toxic effect incidences in sixty locally advanced breast cancer patients subjected to neoadjuvant docetaxel (75 mg/m2) and epirubicin (50 mg/m2) combination.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

  Toxicity (%)
Alopecia 100
Nausea and vomiting 19.2
Neutropenia 11.5
Febrile neutropenia 3.8
Fever 5.7
Diarrhea 5.7
Mucositis 3.8
Allergic reactions 3.8
Asthenia 1.9
Headache 1.9